Innoviva, Inc. (INVA) Stock
NSQ · INVA
20.66
Fundamentals
Market cap
$1.50B
Price / Earnings ratio
4.2x
Price / Sales ratio
3.4x
Price / Book ratio
1.2x
Return on assets
32.0%
Ex-Dividend date
8 Sep 2015
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
Innoviva to Participate in Upcoming Investor Conferences
NeutralINVASeptember 2, 2026
Business WireNeutral
Innoviva to Participate in Upcoming Investor Conferences
INVA

Business Wire
Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
NeutralINVAAugust 11, 2026
Business WireNeutral
Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
INVA

Zacks Investment Research
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
NeutralINVAAugust 6, 2026
Zacks Investment ResearchNeutral
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
INVA

Business Wire
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
NeutralINVAAugust 5, 2026
Business WireNeutral
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
INVA
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
494M326M163M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
2B1B648M0
Revenue to Profit
2025$411.3M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$271.2M
Net incomeEarnings
EPS forecast
Actual EPS
$0.39
Q4FY25
$0.41
Q1FY26
$0.72
Q2FY26
The market is expecting earnings per share of $0.72 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
Innoviva to Participate in Upcoming Investor Conferences
NeutralINVASeptember 2, 2026
Business WireNeutral
Innoviva to Participate in Upcoming Investor Conferences
INVA

Business Wire
Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
NeutralINVAAugust 11, 2026
Business WireNeutral
Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
INVA

Zacks Investment Research
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
NeutralINVAAugust 6, 2026
Zacks Investment ResearchNeutral
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
INVA

Business Wire
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
NeutralINVAAugust 5, 2026
Business WireNeutral
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
INVA

MarketBeat
Supernus Pharmaceuticals Q2 Earnings Call Highlights
NeutralINVAAugust 3, 2026
MarketBeatNeutral
Supernus Pharmaceuticals Q2 Earnings Call Highlights
INVA

Business Wire
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
NeutralINVAJune 18, 2026
Business WireNeutral
Nortiva Bio Launches to Develop Long-Acting Oral Medicines
INVA

Business Wire
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets
NeutralINVAJune 16, 2026
Business WireNeutral
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy's for XACDURO® in Select International Markets
INVA

Business Wire
Innoviva to Participate in Upcoming Investor Conferences
NeutralINVAJune 1, 2026
Business WireNeutral
Innoviva to Participate in Upcoming Investor Conferences
INVA

Zacks Investment Research
Innoviva (INVA) Tops Q1 Earnings Estimates
NeutralINVAMay 7, 2026
Zacks Investment ResearchNeutral
Innoviva (INVA) Tops Q1 Earnings Estimates
INVA

Business Wire
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
NeutralINVAMay 6, 2026
Business WireNeutral
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
INVA
About Innoviva, Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
SectorHealthcare
IndustryBiotechnology
Employees159
CEOMr. Pavel Raifeld C.F.A.
IPO DateOct 5, 2004
HeadquartersBurlingame, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Pavel Raifeld C.F.A. | CEO & Director | 1984 |
| Mr. Stephen Basso M.B.A. | Chief Financial Officer | 1966 |
| Ms. Marianne Zhen CPA | Chief Accounting Officer & Secretary | 1969 |
| Ms. Patricia M. Drake | Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc. | 1967 |
| Dr. David Altarac M.D., MPA | Chief Medical Officer of IST | 1962 |
Fundamentals
Valuation
Market cap$1.50B
Price-to-sales ratio3.39
Price-to-book value1.21
Price-earnings ratio4.20
Return on Equity48.00%
Return on Sales147.00%
Return on Assets32.00%
PEG ratio0.25
Earnings Per Share
Earnings Per Share$5.05
Income Statement
Average volume962,661
EBITDA$657.74M
1 year high (52w)$25.15
1 year low (52w)$16.52
Dividend
Ex dividend date8 Sep 2015
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$34.50
Est return
66.35%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.1 | +2.5 | -3.8 | +3.9 | ||||||||
| 2022 | -8.1 | +21.6 | +3.6 | -13.6 | -7.0 | +0.3 | -3.7 | -8.0 | -10.8 | +14.9 | -3.1 | +0.5 |
| 2023 | -4.7 | -5.3 | -1.1 | +3.0 | +15.4 | -2.9 | +6.8 | -4.6 | +1.3 | -4.3 | +11.5 | +14.7 |
| 2024 | -1.0 | -6.2 | +0.0 | -0.7 | +3.7 | +3.1 | +14.2 | +0.5 | -1.1 | +0.3 | -1.4 | -9.3 |
| 2025 | +7.1 | -2.7 | +1.9 | +4.2 | +4.9 | -0.2 | -8.2 | +9.7 | -12.6 | +0.2 | +20.0 | -5.5 |
| 2026 | +0.7 | +9.4 | +2.1 | -1.8 | -7.3 | +5.6 | -4.2 | +0.0 | -1.6 |



